Xunming Bio completed a Series B financing round totaling $100 million.

On August 11, Xunming Biotechnology announced that it has completed a Series B financing round totaling 100 million USD. Xunming Biotechnology stated that this round of financing was completed in phases, with the first round exclusively invested by Granite Asia, followed by subsequent rounds led by renowned industry investors, with Honghui Fund participating, and existing shareholders such as Qiming Venture Partners, Jingwei China, and Newbury Capital continuing to invest. With this, Xunming Biotechnology has raised nearly 200 million USD in total financing. Xunming Biotechnology revealed that the funds from this round of financing will be primarily used for the research and development and scaled training of a new generation of bio-based platform models.